عربي
Vifor Pharma supports Iron Deficiency Day 2020 to highlight global impact on health and gender inequality ST GALLEN, Switzerland -Thursday 26 November 2020
In its sixth year, a growing international coalition underlines significant harm to health caused by iron deficiency Impact on women moves up political agenda at REYKJAVÍK GLOBAL FORUM - WOMEN LEADERS 2020 This year the focus is on raising awareness of symptoms, importance of diagnosis...
VFMCRP and Fresenius Kabi expand collaboration in nephrology in China with Veltassa® agreement
...
-Thursday 19 November 2020 
(BUSINESS WIRE) -- Regulatory News: Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and Fresenius Kabi today announced an agreement to develop, register and distribute Veltassa® for the treatment of hyperkalemia in the People’s Republic of China. Under the agreement, Fresenius Kabi...
Full Results From AFFIRM-AHF Study Show Ferinject® Significantly Reduces Hospitalizations After... -Saturday 14 November 2020
(BUSINESS WIRE) -- Regulatory News: Vifor Pharma today presented the full results from the AFFIRM-AHF study at the 2020 American Heart Association (AHA) Scientific Sessions virtual congress. Simultaneously, results were published in the peer-reviewed medical journal The Lancet. The study...
Vifor Pharma and Angion Sign License Agreement for ANG-3777 in Nephrology Indications
-Monday 9 November 2020
Vifor Pharma acquires a worldwide license, excluding Greater China, to late-stage product ANG-3777 ANG-3777 is a first in class small-molecule hepatocyte growth factor (HGF) mimetic, addressing a significant unmet need for the treatment of delayed graft function and cardiac...
VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization...
-Tuesday 3 November 2020
Companies have completed the EU regulatory application for marketing approval of avacopan Regulatory submission based on positive data from the pivotal phase-III ADVOCATE trial of avacopan (BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full...
Vifor Pharma and Cara Therapeutics sign US license agreement for i.v. Korsuva™* to treat dialysis patients with...
-Tuesday 20 October 2020
(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201019005725/en/ Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq:CARA) today announced that both companies have signed a license agreement for...
Vifor Pharma announces outcome of AFFIRM-AHF topline data -Thursday 24 September 2020
The study narrowly missed statistical significance on the primary endpoint Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage The totality of evidence suggests that Ferinject® is clinically beneficial in high risk heart failure...
Vifor Pharma Group Announces Successful Sale of OM Pharma -Friday 18 September 2020
Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435 In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity which could increase the total transaction value in excess of MCHF 500...
Vifor Pharma Appoints Gregory Oakes as President North America and Member of the Executive Committee -Tuesday 1 September 2020
(BUSINESS WIRE)-- Regulatory News: Vifor Pharma today announced the appointment of Gregory Oakes as EVP, President North America and member of the Vifor Pharma Executive Committee as of September 1, 2020. Gregory Oakes has a proven track record of building and leading organizations across...
Vifor Pharma Group Reports Continued Growth in H1 2020
-Thursday 6 August 2020
Net sales and EBITDA continued to grow in H1 2020 despite challenging market conditions due to COVID-19 Ferinject®/ Injectafer® demand impacted by global COVID-19 restrictions Sustained growth in nephrology supported by dialysis business Veltassa® net sales impacted by reduced...
VFMCRP and ChemoCentryx announce topline data from phase-II LUMINA-1 trial of CCX140 in Focal Segmental...
-Monday 18 May 2020
(BUSINESS WIRE)-- Regulatory News: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200517005052/en/ Vifor Fresenius Medical Care Renal Pharma (VFMCRP) and ChemoCentryx, Inc., (NASDAQ: CCXI) today announced topline data from a...
92nd Vifor Pharma Group Annual General Meeting
-Thursday 14 May 2020
(BUSINESS WIRE) -- Regulatory News: At the 92nd Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. In view of the current situation and based on Art. 6a of Ordinance 2, issued by the Swiss Federal Council,...
Vifor Pharma Announces Akebia’s Positive Top-Line Results From Global Phase-III Program of vadadustat for... -Tuesday 5 May 2020
(BUSINESS WIRE)-- Regulatory News: Vifor Pharma announced that its partner, Akebia Therapeutics, Inc., today reported positive top-line results from INNO2VATE, Akebia’s global phase-III cardiovascular outcomes program evaluating the efficacy and safety of vadadustat, an investigational...
Vifor Pharma Group Reports Strong Growth in 2019, Exceeding Raised Guidance -Thursday 12 March 2020
(BUSINESS WIRE) -- Regulatory News: Vifor Pharma Group recorded strong financial and operational performance in 2019 by focusing on its three strategic growth drivers while continuing to invest in its pipeline. The company exceeded its raised guidance for full-year 2019 on both net sales and...
Pioneering Project for Pharmaceutics – Vifor Pharma and the University of Basel are Jointly Establishing the...
-Sunday 26 May 2019
(BUSINESS WIRE) -- Nanopharmaceutics promises ground-breaking innovation in the development of medicines: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190526005014/en/ The Vifor Pharma Group is endowing two professorships...
Permalink :- http://aetoswire.com/newsroom/1/vifor-pharma